These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 228166)

  • 21. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
    Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
    Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mapping of antigenic domains in poliovirus VP1 involved in structural rearrangements during virus morphogenesis and antigenic alterations of the virion.
    Ketterlinus R; Wiegers K
    Virology; 1994 Oct; 204(1):27-37. PubMed ID: 7522372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poliovirus neutralization by antibodies to internal epitopes of VP4 and VP1 results from reversible exposure of these sequences at physiological temperature.
    Li Q; Yafal AG; Lee YM; Hogle J; Chow M
    J Virol; 1994 Jun; 68(6):3965-70. PubMed ID: 7514682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isolation of escape mutants of a hybrid poliovirus with the aid of insert-specific polyclonal antibodies.
    Hovi T; Huovilainen A; Murdin A; Wimmer E
    J Gen Virol; 1995 Jul; 76 ( Pt 7)():1861-5. PubMed ID: 9049393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding of neutralizing monoclonal antibodies to empty capsids of poliovirus can be blocked by monospecific antisera to structural polypeptides VP1 and VP2.
    Uhlig H; Haardt F; Dernick R
    Arch Virol; 1985; 83(3-4):295-303. PubMed ID: 2578787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of neutralizing antibodies by all three structural poliovirus polypeptides.
    Dernick R; Heukeshoven J; Hilbrig M
    Virology; 1983 Oct; 130(1):243-6. PubMed ID: 6314647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electron microscopic examination of the reactivity of three kinds of neutralizing antibodies with H particles of poliovirus.
    Taniguchi K; Urasawa S; Urasawa T
    Microbiol Immunol; 1983; 27(7):645-8. PubMed ID: 6195513
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of site and mode of expression of a heterologous antigenic determinant on the properties of poliovirus hybrids.
    Murdin AD; Mirzayan C; Kameda A; Wimmer E
    Microb Pathog; 1991 Jan; 10(1):27-37. PubMed ID: 1713280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigenicity and immunogenicity of poliovirus capsid proteins.
    van Wezel AL; van der Marel P; Hazendonk TG; Boer-Bak V; Henneke MA
    Dev Biol Stand; 1983; 55():209-15. PubMed ID: 6203795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction and characterization of a poliovirus/rhinovirus antigenic hybrid.
    Altmeyer R; Murdin AD; Harber JJ; Wimmer E
    Virology; 1991 Oct; 184(2):636-44. PubMed ID: 1653493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of neutralizing antibodies by poliovirus capsid polypeptides VP1, VP2 and VP3.
    van der Marel P; Hazendonk TG; Henneke MA; van Wezel AL
    Vaccine; 1983 Dec; 1(1):17-22. PubMed ID: 6099638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the immune response of the rabbit to virulent and attenuated strains of type 1 poliovirus.
    Gaudin OG; Viac J; Thouvenot D; Sohier R
    Bull World Health Organ; 1974; 50(6):479-5. PubMed ID: 4376464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice.
    Martin A; Wychowski C; Couderc T; Crainic R; Hogle J; Girard M
    EMBO J; 1988 Sep; 7(9):2839-47. PubMed ID: 2460345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralization of poliovirus by polyclonal antibodies requires binding of a single IgG molecule per virion.
    Wetz K; Willingmann P; Zeichhardt H; Habermehl KO
    Arch Virol; 1986; 91(3-4):207-20. PubMed ID: 3022677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3.
    Ferguson M; Evans DM; Magrath DI; Minor PD; Almond JW; Schild GC
    Virology; 1985 Jun; 143(2):505-15. PubMed ID: 2414909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection by monoclonal antibodies of an antigenic determinant critical for poliovirus neutralization present on VP1 and on heat-inactivated virions.
    Blondel B; Akacem O; Crainic R; Couillin P; Horodniceanu F
    Virology; 1983 Apr; 126(2):707-10. PubMed ID: 6190311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A neutralizing monoclonal antibody against poliovirus and its reaction with related antigens.
    Icenogle J; Gilbert SF; Grieves J; Anderegg J; Rueckert R
    Virology; 1981 Nov; 115(1):211-5. PubMed ID: 6270899
    [No Abstract]   [Full Text] [Related]  

  • 38. Mapping of type 1 poliovirus neutralization epitopes.
    Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
    Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-AgIB of poliovirus type 1: a discontinuous epitope formed by two loops of VP1 comprising residues 96-104 and 141-152.
    Wiegers K; Uhlig H; Dernick R
    Virology; 1989 Jun; 170(2):583-6. PubMed ID: 2471354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.